Menopause could lead to weight gain (Credits: Canva)
There are many phases in a woman's life, menarche, menstruations, pregnancy, postpartum and menopause. Each phase comes with its own challenges, and changes the way of looking at life. However, narrowing to one, today we are focusing on weight gain after menopause. Gaining weight is a common concern for many women are approaching menopause. This period brings hormonal changes, shifts in activity levels and effects of aging. All of these contribute to weight gain. However, not everyone experiences weight gain during menopause, and individual experiences may vary greatly.
Before diving into the specifics of weight gain, it’s helpful to understand the terminology associated with menopause:
Hormones influence weight fluctuations after menopause, specifically how fat is distributed and how the body controls hunger.
The hormonal fluctuations of perimenopause and menopause influence where fat is stored in the body:
Perimenopause: During this phase, estrogen levels fluctuate while progesterone levels decline steadily. In early perimenopause, higher estrogen levels can promote fat storage in the hips and thighs as subcutaneous fat, which generally carries fewer health risks.
Menopause: As estrogen levels drop significantly, fat storage shifts to the abdominal area as visceral fat.
This type of fat surrounds internal organs and is associated with health risks like:
Lower estrogen levels during perimenopause can have an impact on appetite management. A 2019 analysis found that decreased estrogen may diminish satiety signals, making you feel less full after meals. This might lead to increased calorie consumption and weight gain.
Weight gain during menopause is attributed to more than just hormonal changes. Several elements come into play throughout the aging process:
Increased fat content and decreased muscle mass: These changes affect the body's resting energy expenditure (REE), which means fewer calories are expended when at rest.
Lower activity levels: Fatigue, sleep difficulties, and menopause-related symptoms can all lead to a decrease in physical activity, further reducing REE and increasing weight.
If you are concerned about weight gain during menopause, a variety of strategies can help you manage it effectively. It is usually recommended that you speak with a healthcare practitioner before developing a specific approach.
Focus on a well-balanced diet that includes less carbohydrates, more fiber, and less added sugar and salt.
Include nutrient-dense meals to boost overall health.
Regular exercise helps to maintain muscle mass and reduce body fat. Strength training, aerobic, and flexibility exercises are quite beneficial.
If you have osteoporosis, see your doctor about safe activity options.
Prioritize sleep and relaxation to combat fatigue and stress, both of which can contribute to weight gain.
Mindfulness practices or yoga may help reduce stress levels.
Credit: Canva, Canada Insulin
Orforglipron, a new daily pill, may be more effective than existing oral treatments for weight loss and blood sugar control than semaglutide, according to a recent clinical trial.
Semaglutide belongs to a group of drugs known as GLP-1 medications, known to mimic a natural hormone that helps regulate appetite, slow digestion, and control blood sugar. The drug is commonly sold under the brand names Wegovy and Ozempic.
Despite being highly effective, semaglutide usually needs to be injected and requires refrigeration, which can make it inconvenient and harder to access for some patients. Additionally, the drug also carries a high price point.
However, in a 52-week trial involving people with Type 2 Diabetes, orforglipron was found to lower average blood sugar levels more than oral semaglutide and also led to greater weight loss.
Participants taking orforglipron lost around up to eight kilograms on average, compared to about five kilograms with semaglutide. Morever, orforglipron is a once-daily pill that does not require injections or cold storage.
But the study also found that orforglipron caused more side effects, particularly digestive issues like nausea and diarrhea. Yet scientists believe it may still be a better alternative to semaglutide as its easier and cheaper to produce than peptide-based drugs like semaglutide.
They also noticed that the drug absorbed more efficiently by the body and does not require strict timing around meals, unlike current oral versions of semaglutide.
READ MORE: Alkem Laboratories Launches Cheapest Semaglutide Injection In India
The first thing to remember here is that Ozempic is a brand-name medicine that contains semaglutide as its active ingredient. Semglutide is the synthetic version of GLP-1—a natural hormone produced in the intestines that regulates blood sugar, appetite, and digestion. Now, every time you eat, your body produces various hormones, including GLP-1. These are called Post nutrition hormones, and help you absorb the energy you just consumed.
GLP-1 travels to your pancreas, prompting it to produce insulin. It also travels to the hypothalamus in your brain, which gives you the feeling of being full or satiated. Ozempic imitates this hormone, thereby, silencing the food chatter in the brain. Interestingly, for some people this food chatter is really quiet ( people with low appetite) and for others it is an outbrurst, (people who generally binge eat.) So with Ozempic, silencing this self-talk in the brain, people tend to lose their appetite and eventually weight.
However, it is important to note that losing weight includes not just fat but muscle as well. Losing too much muscle can lead to reduced strength and a shorter life span. Notably, records show that most people who start taking them stop it at 12 weeks; therefore, it is important for some but not for others.
As reiterated by doctors and health care experts, Ozempic is a drug that is tasked to help diabetic patients manage their blood sugar levels and weight. However, recent research has shown its effectiveness in mitigating various addictions like alcohol and drugs by inhibiting hormones. But what people ignore are its side effects, which include:
Credit: Canva
People with blood type B, either positive or negative, are 28 percent more likely to develop Type 2 diabetes, according to a 2024 BMC Medicine study.
Human blood is categorized into eight main groups based on the sugars and proteins, or lack thereof, present on the surface of your red blood cells.
A, B, and AB types are based on the presence of antigens, sugar molecules that can trigger an immune response. O-type blood has no A or B antigens. Meanwhile, Rhesus (Rh) factors are proteins that determine blood compatibility and give your blood its positive or negative designation.
According to a group of Chinese researchers, who conducted a thorough umbrella review of 270 studies, the strongest link between a blood group and Type 2 diabetes was between those with a B blood group.
The researchers also didn't examine what might drive this increased risk. A 2025 study suggests that the gut microbiome may be involved; however, further investigation is needed.
However, the results do suggest that there's a real, tangible association between blood type and Type 2 diabetes – one that people can factor into how they think about their own risk.
Type 2 diabetes (T2D) occurs when blood sugar (glucose) remains consistently high. Normal blood sugar levels fall between 70 and 99 milligrams per deciliter (mg/dL). If undiagnosed, Type 2 diabetes often shows levels of 126 mg/dL or more.
T2D happens because the pancreas doesn’t produce enough insulin, the body can’t use insulin effectively, or a combination of both. This differs from Type 1 diabetes, which arises when the immune system attacks the pancreas, leaving the body unable to produce insulin at all.
Type 2 diabetes is widespread. Over 37 million people in the US have diabetes (around 1 in 10), with 90–95 percent of cases being T2D. Globally, it affects roughly 6.3 percent of the population. While it’s most common in adults over 45, younger adults and even children can develop it.
The American Diabetes Association recommends the following ranges for adults with type 1 or type 2 diabetes and children with type 2 diabetes:
Recommended Blood Sugar Range
Fasting (before eating): 80 to 130 mg/dL
1 to 2 hours after meal: Lower than 180 mg/dL
T2D has complex causes, but genes play a significant role. If one biological parent has T2D, your lifetime risk is around 40 percent, and if both parents do, it rises to 70%. Scientists have identified over 150 DNA variations linked to T2D risk, some increase the chance of insulin resistance or reduced insulin production, while others influence obesity risk. These genetic factors interact with lifestyle and health habits to determine overall risk.
Doctors use several blood tests to confirm T2D:
Credit: Eisai Co.
Scientists have found a new potential way to treat Alzheimer’s disease and it's already approved by the US Food and Drug Administration.
Researchers at the the Indiana University School of Medicine have found that removing or reducing a specific brain cell enzyme, known as IDOL, can significantly lower the buildup of amyloid plaques while also helping the brain resist further damage.
As of now, Lecanemab and Donanemab drugs can help achieve this as they work by clearing these plaques from the brain and can help slow the progression of symptoms.
However, the researchers' new theory focuses on preventing plaque buildup in the first place, while also improving how brain cells communicate and process fats.
The scientists claim that enzymes such as IDOL are easier to target with drugs due to their well-defined structures, allowing them to design treatments that are more precise and potentially have fewer side effects.
Kim, the P. Michael Conneally Professor of Medical and Molecular Genetics: "What makes this exciting is that we now have a specific target that could lead to a new type of treatment.
"We believe that IDOL will provide us with an alternative strategy to treat Alzheimer’s disease. Targeting enzymes in drug development offers key advantages due to their well-defined active sites or ‘pockets’ where drugs can attach and block their activity. This precision means we can design molecules that hit the right target with minimal side effects."
Kim notes that the team now plans to explore several approaches to target IDOL as part of new Alzheimer’s treatments including testing the safety and effectiveness of potential compounds in preclinical models.
The researchers will also study whether blocking IDOL can help preserve synaptic connections and reduce tau pathology, another key feature of the disease.
READ MORE: The One Critical Thing You Should Do To Prevent Alzheimer's Disease
Alzheimer's disease is one of the most common forms of dementia and mostly affects adults over the age of 65.
About 8.8 million Indians aged 60 and above are estimated to be living with Alzheimer's disease. Over seven million people in the US 65 and older live with the condition and over 100,00 die from it annually.
Alzheimer's disease is believed to be caused by the development of toxic amyloid and beta proteins in the brain, which can accumulate in the brain and damage cells responsible for memory.
Amyloid protein molecules stick together in brain cells, forming clumps called plaques. At the same time, tau proteins twist together in fiber-like strands called tangles. The plaques and tangles block the brain's neurons from sending electrical and chemical signals back and forth.
Over time, this disruption causes permanent damage in the brain that leads to Alzheimer's disease and dementia, causing patients to lose their ability to speak, care for themselves or even respond to the world around them.
While there is no clear cause of Alzheimer's disease, experts believe it can develop due to genetic mutations and lifestyle choices, such as physical inactivity, unhealthy diet and social isolation.
Early symptoms of Alzheimer's disease include forgetting recent events or conversations. Over time, Alzheimer's disease leads to serious memory loss and affects a person's ability to do everyday tasks.
There is no cure for this progressive brain disorder and in advanced stages, loss of brain function can cause dehydration, poor nutrition or infection. These complications can result in death.
The US Food and Drug Administration has approved the use of a blood test which can help diagnose Alzheimer’s disease in adults aged 55 and above.
The blood test, known as Lumipulse, can detect amyloid plaques associated with Alzheimer’s disease and has proven to be a “less invasive option” that “reduces reliance on PET scans and increases diagnosis accessibility.”
FDA Commissioner Martin A. Makary said of the landmark decision, "Alzheimer’s disease impacts too many people, more than breast cancer and prostate cancer combined.
"Knowing that 10 percent of people aged 65 and older have Alzheimer's, and that by 2050 that number is expected to double, I am hopeful that new medical products such as this one will help patients."
It remains unclear when this test will be available for commercial use across the world.
© 2024 Bennett, Coleman & Company Limited